A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia
Authors:
- Gerald V. NaccarelliGNGerald V. Naccarelli
- Philippe CoumelPCPhilippe Coumel
- Stefan H. HohnloserSHStefan H. Hohnloser
- Mary Jane MaserMMMary Jane Maser
- 1 January 1996
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 77 (3) , 89A-95A
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Supraventricular TachycardiaNew England Journal of Medicine, 1995
- FlecainideJournal of Cardiovascular Electrophysiology, 1994
- Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndromeThe American Journal of Cardiology, 1992
- Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.Circulation, 1991
- Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues.Circulation, 1990
- Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizinAmerican Journal of Physiology-Cell Physiology, 1989
- Summary of efficacy and safety of flecainide for supraventricular arrhythmiasThe American Journal of Cardiology, 1988
- Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibersJACC, 1985
- Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.Heart, 1982
- Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.Circulation, 1982